Preparation method and application of core-shell nanoparticles loaded with EBV-LMP2 mRNA

A technology of EBV-LMP2 and nanoparticles, which is applied in the field of core-shell nanoparticles and its preparation, can solve the problems that mRNA vaccines have not been reported in the literature, and achieve the effect of universality, small particle size and uniform particle size

Active Publication Date: 2021-03-09
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF11 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows for the production of nano particles with specific properties that are useful when applied topically or systematically against cancerous cells. These specialized particles may contain certain substances like radioactive materials (radiolabeled) or other agents designed specifically target tumors.

Problems solved by technology

This patented technical problem addressed in this patents relates to finding effective ways to develop novel compositions containing chemoimmunoenhancer (CIM) protein or nucleus cytoskeleton associated factor-1(NCI), which could help reduce lung squamous cell carcenosis caused by certain types of nonsmallancelia disease (NSCD).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method and application of core-shell nanoparticles loaded with EBV-LMP2 mRNA
  • Preparation method and application of core-shell nanoparticles loaded with EBV-LMP2 mRNA
  • Preparation method and application of core-shell nanoparticles loaded with EBV-LMP2 mRNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] The preparation of embodiment 1 cationic liposome

[0041] Prepare LP by thin film dispersion-hydration-ultrasonic method, the specific method is as follows: DOTAP and Chol are prepared as a 10mg / mL stock solution with absolute ethanol, and DOTAP and Chol are added to a 1000mL spinner bottle at a ratio of 1:1 Add corresponding volume of absolute ethanol to 2mL. After the rotary evaporation, the spinner bottle was placed under vacuum conditions to further remove the organic solvent to prepare a lipid film. After film formation, add 2mL RNase-free water to hydrate the lipid film. After the hydration was completed, the obtained crude liposomes were transferred to a 10mL EP tube, and the crude LP solution was crushed with an ultrasonic cell disruptor, with the ultrasonic power set to 80W, ultrasonic for 3s, stop for 3s, and the total ultrasonic time was 3min. The LP obtained after sonication is obtained by filtering it with a 0.22 μm sterile water filter membrane. Further

Embodiment 2

[0042] Preparation and screening of embodiment 2 PLGA nanoparticles

[0043] Weigh 20 mg of PLGA into a 2 mL EP tube, add 1 mL of ethyl acetate solvent to prepare the oil phase. At the same time, weigh 80 mg of PVA into a 10 mL EP tube, add 4 mL of 95° C. RNase-free water to prepare an aqueous phase solution containing 2% (w / v) of PVA. The oil phase was quickly injected into the water phase, and quickly placed in an ice bath for ultrasonic emulsification. The ultrasonic power was 300W, ultrasonic 3s, intermittent 3s, and the total ultrasonic time was set to 3min. After the ultrasonication, the emulsified solution was quickly transferred to an eggplant-shaped bottle, and was obtained by rotary evaporation at 75 rpm in a water bath at 37°C.

[0044] Ultrasound Power Screening

[0045] Weigh 20mg of PLGA and place it in a 2mL EP tube, add 1mL of ethyl acetate, and dissolve it ultrasonically in a water bath to prepare the oil phase. At the same time, weigh 40 mg of PVA into a 10

Embodiment 3

[0052] Preparation and screening of embodiment 3 core-shell nanoparticles

[0053] Ultrasound Power Screening

[0054] The lipid film was prepared according to the preparation method of Example 1, wherein the molar ratio of DOTAP to Chol was 1:1, and the total lipid concentration was 6 mM. Add 2 mL of PLGA nanoparticles prepared in Example 2 into the lipid film for hydration for 30 min, then transfer the hydrated solution to a 10 mL EP tube, and homogenize it by ultrasonic probe. The ultrasonic power was set to 30W, 50W, 80W and 100W respectively, the ultrasonic was 3s, the interval was 3s, and the total ultrasonic time was set to 3min. After the ultrasonic wave was finished, it was measured with a Malvern particle size potential analyzer, and the results are shown in the attached figure 2 .

[0055] It can be seen from the results that the diameter of the coarse core-shell nanoparticles after direct hydration is 279.2±8.8nm, and the PDI is 0.402±0.081. It can be seen that t

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the field of medicines, and particularly relates to a preparation method and application of core-shell nanoparticles loaded with EBV-LMP2 mRNA. The core-shell nanoparticles loaded with EBV-LMP2 mRNA have a good anticancer treatment effect and small toxic and side effects. The core-shell nanoparticles are prepared by taking EBV-LMP2 mRNA as a raw material, and after the core-shell nanoparticles are combined with a carrier, the core-shell nanoparticles can be effectively delivered into cells to express corresponding proteins so as to stimulate the effect of immunotherapy. The core-shell nanoparticles have an obvious treatment effect on diseases caused by EBV viruses, and a new choice is provided for clinical effective application of EBV-LMP2 mRNA.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products